Colorectal Cancer | Specialty

The colorectal cancer condition center is a comprehensive resource for clinical news and expert insights on colorectal cancer. Read more at OncLive.

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

December 23rd 2024

Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.

Ongoing Research Seeks to Optimize Targeted Therapy Use in mCRC

December 22nd 2024

Aparna Parikh, MD, discussed novel agents that are currently at play in the mutated, metastatic colorectal cancer treatment field.

The OncFive: Top Oncology Articles for the Week of 12/15

December 21st 2024

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer

December 20th 2024

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

NGS and ctDNA Testing Guide Treatment Selection and Sequencing in mCRC

December 6th 2024

Cathy Eng, MD, FACP, FASCO, shares insights on biomarker testing and sequencing strategies for patients with colorectal cancer.

Targeted Therapies Represent Core 2024 NCCN GI Cancer Guideline Advancements

November 27th 2024

Alan P. Venook, MD, describes challenges implementing NCCN guidelines into practice in rectal, colon, and biliary tract cancers, and advancements from 2024.

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

November 25th 2024

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

CHMP Recommends Approval of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC

November 15th 2024

The EMA’s CHMP agency recommended approval for nivolumab plus ipilimumab in patients with MSI-H/dMMR unresectable or metastatic colorectal cancer.

GRANITE Plus ICIs and Bevacizumab/Chemo Shows Improved PFS Trend in MSS mCRC

November 15th 2024

GRANITE-based maintenance therapy improved PFS in first-line MSS colorectal cancer.

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

November 7th 2024

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Dr Parikh on Available Treatment Options for HER2+ CRC

November 7th 2024

Aparna Parikh, MD, discusses currently available treatment options for patients with HER2-positive colorectal cancer.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches

October 31st 2024

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

October 30th 2024

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Dr Parikh on Currently Available Targeted Treatment Approaches for Mutated CRC

October 29th 2024

Aparna Parikh, MD, discusses currently available targeted therapy options for patients with colorectal cancer.

Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial

October 28th 2024

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.

ctDNA Generates Momentum in Adjuvant Stage II/III Colon Cancer Setting

October 28th 2024

John L. Marshall, MD, details updates with ctDNA in colorectal cancer, and how precision medicine with ctDNA could change the way patients are treated.

Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD

October 24th 2024

Hear Alan P. Venook, MD, discuss recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal cancers.